Posted by Michael Wonder on 26 Feb 2019
Spero Therapeutics receives QIDP designation from the U.S. FDA for the development of SPR720
26 February 2019 - Phase 1 top-line data readout for oral SPR720 expected in second half of 2019.
Spero Therapeutics announced today that SPR720, an orally administered antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial infections, has been granted qualified infectious disease product designation by the U.S. FDA for the treatment of lung infections caused by non-tuberculous mycobacteria and lung infections caused by Mycobacterium tuberculosis.
SPR720 is currently being evaluated in a Phase 1 double-blind, placebo-controlled clinical trial designed to assess the safety, tolerability and pharmacokinetics of SPR720 in healthy volunteers.
